The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.
Sheena K. Aurora, MD
Advertisement
Vice President, Medical Affairs – Migraine, Impel Neuropharma
Articles by Sheena K. Aurora, MD
The vice president of Medical Affairs in Migraine at Impel discussed the STOP 301 trial of intranasal DHE and how the safety profile offers a positive for patients who would use the agent on-demand.
The vice president of Medical Affairs in Migraine at Impel discussed the gaps in care that novel dihydroergotamine formulations, such as INP104, might be able to fill for patients with migraine.
Advertisement
Latest Updated Articles
The Broad Receptor Profile of DHE: Sheena K. Aurora, MDPublished: June 22nd 2021 | Updated:
- Advantages and Safety Profile of INP104: Sheena K. Aurora, MD
Published: June 23rd 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NeurologyLive® Friday 5 — November 7, 2025
2
Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation
3
ALS Qualitative Study Highlights Complexities of Decision-Making Process for Medical Aid in Dying (MAID)
4
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
5
